input stringlengths 17 568 | output unknown | schema unknown |
|---|---|---|
Although the t-AML developed following oral etoposide therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated. | {
"entities": {
"adverse effect": [
{
"text": "t-AML",
"start": 13,
"end": 18
}
],
"drug": [
{
"text": "etoposide",
"start": 44,
"end": 53
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"text... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause? | {
"entities": {
"adverse effect": [
{
"text": "Secondary leukemia",
"start": 0,
"end": 18
}
],
"drug": [
{
"text": "etoposide",
"start": 63,
"end": 72
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The authors present a case of t-AML that developed in a child with metastatic neuroblastoma 18 months after he received oral etoposide, given for palliation purpose. | {
"entities": {
"adverse effect": [
{
"text": "t-AML",
"start": 30,
"end": 35
}
],
"drug": [
{
"text": "etoposide",
"start": 125,
"end": 134
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"te... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
BACKGROUND: Cyanamide, an aversive agent widely used in Japan, is known to induce various degrees of hepatic lesion with ground-glass inclusion bodies. | {
"entities": {
"drug": [
{
"text": "Cyanamide",
"start": 12,
"end": 21
}
],
"adverse effect": [
{
"text": "hepatic lesion with ground-glass inclusion bodies",
"start": 101,
"end": 150
}
]
},
"relations": {
"adverse effect... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Case 2: A 43-year-old male alcoholic remained completely abstinent with cyanamide treatment for 5 years and complained of general fatigue. | {
"entities": {
"drug": [
{
"text": "cyanamide",
"start": 72,
"end": 81
}
],
"adverse effect": [
{
"text": "general fatigue",
"start": 122,
"end": 137
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Case 3: A 29-year-old female alcoholic complained of general fatigue and a slight fever after 1.5 years of abstinence with cyanamide treatment. | {
"entities": {
"adverse effect": [
{
"text": "fatigue",
"start": 61,
"end": 68
},
{
"text": "fever",
"start": 82,
"end": 87
}
],
"drug": [
{
"text": "cyanamide",
"start": 123,
"end": 132
}
]
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Case 4: A 61-year-old male alcoholic who remained completely abstinent while taking cyanamide for 3 years showed slight elevation of serum transaminases. | {
"entities": {
"drug": [
{
"text": "cyanamide",
"start": 84,
"end": 93
}
],
"adverse effect": [
{
"text": "elevation of serum transaminases",
"start": 120,
"end": 152
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
CONCLUSION: In some abstainers who take cyanamide for several years, thin septum-like liver fibrosis progresses along with the emergence of ground-glass hepatocytes. | {
"entities": {
"drug": [
{
"text": "cyanamide",
"start": 40,
"end": 49
}
],
"adverse effect": [
{
"text": "septum-like liver fibrosis",
"start": 74,
"end": 100
},
{
"text": "ground-glass hepatocytes",
"start": 1... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Cyanamide-induced liver dysfunction after abstinence in alcoholics: a long-term follow-up study on four cases. | {
"entities": {
"drug": [
{
"text": "Cyanamide",
"start": 0,
"end": 9
}
],
"adverse effect": [
{
"text": "liver dysfunction",
"start": 18,
"end": 35
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
When cyanamide-treated alcoholics relapse into drinking, more severe inflammation develops in the liver. | {
"entities": {
"drug": [
{
"text": "cyanamide",
"start": 5,
"end": 14
}
],
"adverse effect": [
{
"text": "inflammation",
"start": 69,
"end": 81
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
A patient with an allergy to a macrolide antibiotic was given tacrolimus and developed a sudden cutaneous reaction. | {
"entities": {
"drug": [
{
"text": "tacrolimus",
"start": 62,
"end": 72
}
],
"adverse effect": [
{
"text": "sudden cutaneous reaction",
"start": 89,
"end": 114
}
]
},
"relations": {
"adverse effect": [
{
"he... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma. | {
"entities": {
"adverse effect": [
{
"text": "nonconvulsive status epilepticus",
"start": 69,
"end": 101
}
],
"drug": [
{
"text": "morphine",
"start": 141,
"end": 149
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone. | {
"entities": {
"adverse effect": [
{
"text": "generalized tonic-clonic seizure",
"start": 2,
"end": 34
}
],
"drug": [
{
"text": "naloxone",
"start": 101,
"end": 109
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Nonconvulsive status epilepticus: the role of morphine and its antagonist. | {
"entities": {
"adverse effect": [
{
"text": "Nonconvulsive status epilepticus",
"start": 0,
"end": 32
}
],
"drug": [
{
"text": "morphine",
"start": 46,
"end": 54
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy. | {
"entities": {
"adverse effect": [
{
"text": "bacterial peritonitis",
"start": 12,
"end": 33
}
],
"drug": [
{
"text": "vasopressin",
"start": 59,
"end": 70
}
]
},
"relations": {
"adverse effect": [
{
"head":... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Although the literature on the use of risperidone in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms (EPS). | {
"entities": {
"drug": [
{
"text": "risperidone",
"start": 38,
"end": 49
}
],
"adverse effect": [
{
"text": "extrapyramidal symptoms",
"start": 276,
"end": 299
},
{
"text": "EPS",
"start": 301,
"end": 30... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Three months following splenectomy, multiple abscesses occurred in the muscles of both thighs while the patient was receiving the third course of the CHOP regimen. | {
"entities": {
"adverse effect": [
{
"text": "multiple abscesses",
"start": 36,
"end": 54
}
],
"drug": [
{
"text": "CHOP",
"start": 150,
"end": 154
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor. | {
"entities": {
"drug": [
{
"text": "ethambutol",
"start": 88,
"end": 98
}
],
"adverse effect": [
{
"text": "polyarthritis",
"start": 129,
"end": 142
},
{
"text": "rash",
"start": 144,
"end": 148
},... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin. | {
"entities": {
"adverse effect": [
{
"text": "Polyarthritis",
"start": 0,
"end": 13
},
{
"text": "hepatitis",
"start": 15,
"end": 24
},
{
"text": "anti-native DNA antibodies",
"start": 29,
"end": 55
}
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
A case of normotensive scleroderma renal crisis after high-dose methylprednisolone treatment. | {
"entities": {
"adverse effect": [
{
"text": "normotensive scleroderma renal crisis",
"start": 10,
"end": 47
}
],
"drug": [
{
"text": "methylprednisolone",
"start": 64,
"end": 82
}
]
},
"relations": {
"adverse effect": [
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
HUS has been reported after several anticancer chemotherapies and most often after mitomycin C-based chemotherapy regimens. | {
"entities": {
"adverse effect": [
{
"text": "HUS",
"start": 0,
"end": 3
}
],
"drug": [
{
"text": "mitomycin C",
"start": 83,
"end": 94
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"text":... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine. | {
"entities": {
"adverse effect": [
{
"text": "Severe hemolytic uremic syndrome",
"start": 0,
"end": 32
}
],
"drug": [
{
"text": "carboplatin",
"start": 84,
"end": 95
},
{
"text": "gemcitabine",
"start": 100,
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We present a case of HUS in an advanced ovarian cancer patient treated with carboplatin and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up. | {
"entities": {
"adverse effect": [
{
"text": "HUS",
"start": 21,
"end": 24
}
],
"drug": [
{
"text": "carboplatin",
"start": 76,
"end": 87
},
{
"text": "gemcitabine",
"start": 92,
"end": 103
}
]... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | {
"entities": {
"drug": [
{
"text": "valproate",
"start": 117,
"end": 126
}
],
"adverse effect": [
{
"text": "menstrual cycle disturbances",
"start": 168,
"end": 196
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy. | {
"entities": {
"adverse effect": [
{
"text": "Reproductive endocrine disorders",
"start": 12,
"end": 44
},
{
"text": "menstrual disorders",
"start": 62,
"end": 81
},
{
"text": "polycystic ovaries",
"start": 83,
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
CONCLUSIONS: The 3 cases presented here illustrate the development of reproductive endocrine disorders after the initiation of valproate therapy in women with epilepsy. | {
"entities": {
"adverse effect": [
{
"text": "reproductive endocrine disorders",
"start": 70,
"end": 102
}
],
"drug": [
{
"text": "valproate",
"start": 127,
"end": 136
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
OBJECTIVE: To describe the development of valproate-related reproductive endocrine disorders in women with epilepsy. | {
"entities": {
"drug": [
{
"text": "valproate",
"start": 42,
"end": 51
}
],
"adverse effect": [
{
"text": "reproductive endocrine disorders",
"start": 60,
"end": 92
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
PATIENTS: Three patients developed a reproductive endocrine disorder during treatment with valproate. | {
"entities": {
"adverse effect": [
{
"text": "reproductive endocrine disorder",
"start": 37,
"end": 68
}
],
"drug": [
{
"text": "valproate",
"start": 91,
"end": 100
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
RESULTS: Replacing valproate with lamotrigine resulted in a decrease in serum testosterone concentrations in all 3 women. | {
"entities": {
"drug": [
{
"text": "valproate",
"start": 19,
"end": 28
}
],
"adverse effect": [
{
"text": "serum testosterone",
"start": 72,
"end": 90
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication. | {
"entities": {
"adverse effect": [
{
"text": "polycystic changes",
"start": 4,
"end": 22
},
{
"text": "gained weight",
"start": 136,
"end": 149
},
{
"text": "amenorrhea",
"start": 164,
"end": 174
}
],
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
However, recurrent staphylococcus aureus sepsis developed during CyA therapy. | {
"entities": {
"adverse effect": [
{
"text": "staphylococcus aureus sepsis",
"start": 19,
"end": 47
}
],
"drug": [
{
"text": "CyA",
"start": 65,
"end": 68
}
]
},
"relations": {
"adverse effect": [
{
"head": ... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis. | {
"entities": {
"adverse effect": [
{
"text": "septicemia",
"start": 10,
"end": 20
},
{
"text": "lethal",
"start": 26,
"end": 32
}
],
"drug": [
{
"text": "cyclosporine",
"start": 58,
"end": 70
}
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
A 60 year-old woman with chronic renal failure developed acute proximal muscle weakness after receiving a regular dosage of colchicine. | {
"entities": {
"adverse effect": [
{
"text": "proximal muscle weakness",
"start": 63,
"end": 87
}
],
"drug": [
{
"text": "colchicine",
"start": 124,
"end": 134
}
]
},
"relations": {
"adverse effect": [
{
"he... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Colchicine-induced myopathy in renal failure. | {
"entities": {
"drug": [
{
"text": "Colchicine",
"start": 0,
"end": 10
}
],
"adverse effect": [
{
"text": "myopathy",
"start": 19,
"end": 27
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"t... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of colchicine-induced myopathy. | {
"entities": {
"adverse effect": [
{
"text": "variation in muscle fiber size",
"start": 23,
"end": 53
},
{
"text": "vacuolated fibers",
"start": 62,
"end": 79
},
{
"text": "myopathy",
"start": 122,
"end": 130
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel. | {
"entities": {
"adverse effect": [
{
"text": "disabling neurotoxicity",
"start": 28,
"end": 51
}
],
"drug": [
{
"text": "paclitaxel",
"start": 133,
"end": 143
}
]
},
"relations": {
"adverse effect": [
{
"hea... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Phantom limb pain as a manifestation of paclitaxel neurotoxicity. | {
"entities": {
"adverse effect": [
{
"text": "Phantom limb pain",
"start": 0,
"end": 17
},
{
"text": "neurotoxicity",
"start": 51,
"end": 64
}
],
"drug": [
{
"text": "paclitaxel",
"start": 40,
"end": 50
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Physicians should be aware that PLP can occur after initiation of paclitaxel. | {
"entities": {
"adverse effect": [
{
"text": "PLP",
"start": 32,
"end": 35
}
],
"drug": [
{
"text": "paclitaxel",
"start": 66,
"end": 76
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"text"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy. | {
"entities": {
"adverse effect": [
{
"text": "phantom limb pain",
"start": 61,
"end": 78
},
{
"text": "PLP",
"start": 80,
"end": 83
}
],
"drug": [
{
"text": "paclitaxel",
"start": 101,
"end": 111
}... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Skin manifestations of a case of phenylbutazone-induced serum sickness-like reactions. | {
"entities": {
"adverse effect": [
{
"text": "Skin manifestations",
"start": 0,
"end": 19
},
{
"text": "serum sickness-like reactions",
"start": 56,
"end": 85
}
],
"drug": [
{
"text": "phenylbutazone",
"start": ... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Our experience supports hemodialysis for ESRF patients with atenolol toxicity. | {
"entities": {
"drug": [
{
"text": "atenolol",
"start": 60,
"end": 68
}
],
"adverse effect": [
{
"text": "atenolol toxicity",
"start": 60,
"end": 77
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Allergic reaction to gemfibrozil manifesting as eosinophilic gastroenteritis. | {
"entities": {
"drug": [
{
"text": "gemfibrozil",
"start": 21,
"end": 32
}
],
"adverse effect": [
{
"text": "eosinophilic gastroenteritis",
"start": 48,
"end": 76
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We describe a case of EGE manifested as an allergy to gemfibrozil. | {
"entities": {
"adverse effect": [
{
"text": "EGE",
"start": 22,
"end": 25
}
],
"drug": [
{
"text": "gemfibrozil",
"start": 54,
"end": 65
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"text... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
This is the second report of lactic acidosis in a patient on stavudine and lamivudine. | {
"entities": {
"adverse effect": [
{
"text": "lactic acidosis",
"start": 29,
"end": 44
}
],
"drug": [
{
"text": "stavudine",
"start": 61,
"end": 70
},
{
"text": "lamivudine",
"start": 75,
"end": 85
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine. | {
"entities": {
"adverse effect": [
{
"text": "lactic acidosis",
"start": 53,
"end": 68
}
],
"drug": [
{
"text": "stavudine",
"start": 72,
"end": 81
},
{
"text": "lamivudine",
"start": 86,
"end": 96
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Ataxia caused by propafenone has been reported to the pharmaceutical companies and drug monitoring agencies, but has not been well described or emphasized in the medical literature. | {
"entities": {
"adverse effect": [
{
"text": "Ataxia",
"start": 0,
"end": 6
}
],
"drug": [
{
"text": "propafenone",
"start": 17,
"end": 28
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"tex... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
A wide variety of adverse central nervous system effects have been reported in association with propafenone; dizziness is the most common. | {
"entities": {
"adverse effect": [
{
"text": "adverse central nervous system effects",
"start": 18,
"end": 56
},
{
"text": "dizziness",
"start": 109,
"end": 118
}
],
"drug": [
{
"text": "propafenone",
"start": 9... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Propafenone-induced ataxia: report of three cases. | {
"entities": {
"drug": [
{
"text": "Propafenone",
"start": 0,
"end": 11
}
],
"adverse effect": [
{
"text": "ataxia",
"start": 20,
"end": 26
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"te... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We describe 3 elderly patients with moderate to severe ataxia that occurred while they were taking propafenone. | {
"entities": {
"adverse effect": [
{
"text": "ataxia",
"start": 55,
"end": 61
}
],
"drug": [
{
"text": "propafenone",
"start": 99,
"end": 110
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
A 74-year-old man received oral administration of pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed loss of consciousness two days later. | {
"entities": {
"drug": [
{
"text": "pilsicainide",
"start": 50,
"end": 62
}
],
"adverse effect": [
{
"text": "loss of consciousness",
"start": 195,
"end": 216
}
]
},
"relations": {
"adverse effect": [
{
"hea... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
When pilsicainide is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid life-threatening arrhythmias due to high plasma concentrations of the drug. | {
"entities": {
"drug": [
{
"text": "pilsicainide",
"start": 5,
"end": 17
}
],
"adverse effect": [
{
"text": "life-threatening arrhythmias",
"start": 133,
"end": 161
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification. | {
"entities": {
"drug": [
{
"text": "risperidone",
"start": 108,
"end": 119
}
],
"adverse effect": [
{
"text": "dystonia",
"start": 151,
"end": 159
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients. | {
"entities": {
"adverse effect": [
{
"text": "non-convulsive status epilepticus",
"start": 15,
"end": 48
}
],
"drug": [
{
"text": "tiagabine",
"start": 52,
"end": 61
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages. | {
"entities": {
"adverse effect": [
{
"text": "non-convulsive status epilepticus",
"start": 14,
"end": 47
}
],
"drug": [
{
"text": "tiagabine",
"start": 80,
"end": 89
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients. | {
"entities": {
"adverse effect": [
{
"text": "non-convulsive status epilepticus",
"start": 28,
"end": 61
}
],
"drug": [
{
"text": "tiagabine",
"start": 74,
"end": 83
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
There have been many reports of probable lithium-induced organic brain syndromes occurring when serum lithium levels are within or close to the therapeutic range. | {
"entities": {
"drug": [
{
"text": "lithium",
"start": 41,
"end": 48
}
],
"adverse effect": [
{
"text": "organic brain syndromes",
"start": 57,
"end": 80
}
]
},
"relations": {
"adverse effect": [
{
"head": {... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium neurotoxicity. | {
"entities": {
"adverse effect": [
{
"text": "psychotic symptoms",
"start": 54,
"end": 72
},
{
"text": "intense anxiety",
"start": 77,
"end": 92
},
{
"text": "neurotoxicity",
"start": 181,
"end": 194
}
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Protease inhibitor-induced carbamazepine toxicity. | {
"entities": {
"drug": [
{
"text": "carbamazepine",
"start": 27,
"end": 40
}
],
"adverse effect": [
{
"text": "carbamazepine toxicity",
"start": 27,
"end": 49
}
]
},
"relations": {
"adverse effect": [
{
"hea... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity. | {
"entities": {
"drug": [
{
"text": "ritonavir",
"start": 21,
"end": 30
},
{
"text": "saquinavir",
"start": 35,
"end": 45
},
{
"text": "carbamazepine",
"start": 131,
"end": 144
}
],
"adverse effect"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity. | {
"entities": {
"drug": [
{
"text": "Ritonavir",
"start": 0,
"end": 9
}
],
"adverse effect": [
{
"text": "diminishing carbamazepine metabolism",
"start": 39,
"end": 75
},
{
"text": "increase in serum levels",
"st... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The patient was diagnosed with carbamazepine toxicity related to the introduction of ritonavir. | {
"entities": {
"drug": [
{
"text": "carbamazepine",
"start": 31,
"end": 44
},
{
"text": "ritonavir",
"start": 85,
"end": 94
}
],
"adverse effect": [
{
"text": "carbamazepine toxicity",
"start": 31,
"end"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Anaphylaxis to calcitonin. | {
"entities": {
"adverse effect": [
{
"text": "Anaphylaxis",
"start": 0,
"end": 11
}
],
"drug": [
{
"text": "calcitonin",
"start": 15,
"end": 25
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
CONCLUSION: We have introduced a case of anaphylaxis by calcitonin that suggest an IgE mediated hypersensitivity reaction. | {
"entities": {
"adverse effect": [
{
"text": "anaphylaxis",
"start": 41,
"end": 52
}
],
"drug": [
{
"text": "calcitonin",
"start": 56,
"end": 66
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The intramuscular challenge test with 25 UI of Miacalcic was positive with an immediate anaphylactic reaction. | {
"entities": {
"drug": [
{
"text": "Miacalcic",
"start": 47,
"end": 56
}
],
"adverse effect": [
{
"text": "anaphylactic reaction",
"start": 88,
"end": 109
}
]
},
"relations": {
"adverse effect": [
{
"head": ... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar). | {
"entities": {
"adverse effect": [
{
"text": "rhinitis",
"start": 81,
"end": 89
},
{
"text": "conjunctivitis",
"start": 91,
"end": 105
},
{
"text": "perspiration",
"start": 110,
"end": 122
}
],
"dr... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Minocycline as a cause of drug-induced autoimmune hepatitis. | {
"entities": {
"drug": [
{
"text": "Minocycline",
"start": 0,
"end": 11
}
],
"adverse effect": [
{
"text": "autoimmune hepatitis",
"start": 39,
"end": 59
}
]
},
"relations": {
"adverse effect": [
{
"head": {... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Minocycline-induced autoimmune hepatitis is usually identical to sporadic autoimmune hepatitis. | {
"entities": {
"drug": [
{
"text": "Minocycline",
"start": 0,
"end": 11
}
],
"adverse effect": [
{
"text": "autoimmune hepatitis",
"start": 20,
"end": 40
}
]
},
"relations": {
"adverse effect": [
{
"head": {... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We describe the clinical and liver biopsy morphologic features for 4 patients with minocycline-induced autoimmune hepatitis (group 1). | {
"entities": {
"drug": [
{
"text": "minocycline",
"start": 83,
"end": 94
}
],
"adverse effect": [
{
"text": "autoimmune hepatitis",
"start": 103,
"end": 123
}
]
},
"relations": {
"adverse effect": [
{
"head"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
L-asparaginase-provoked seizures as singular expression of central nervous toxicity. | {
"entities": {
"drug": [
{
"text": "L-asparaginase",
"start": 0,
"end": 14
}
],
"adverse effect": [
{
"text": "seizures",
"start": 24,
"end": 32
},
{
"text": "central nervous toxicity",
"start": 59,
"end... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Patients treated with L-asparaginase may present with hemorrhagic and thrombotic cerebrovascular events. | {
"entities": {
"drug": [
{
"text": "L-asparaginase",
"start": 22,
"end": 36
}
],
"adverse effect": [
{
"text": "hemorrhagic",
"start": 54,
"end": 65
},
{
"text": "thrombotic cerebrovascular events",
"start": 70,... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We report a case of seizure associated with L-asparaginase therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events. | {
"entities": {
"adverse effect": [
{
"text": "seizure",
"start": 20,
"end": 27
}
],
"drug": [
{
"text": "L-asparaginase",
"start": 44,
"end": 58
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Eighty-two patients with various malignancies who received imipenem/cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified. | {
"entities": {
"drug": [
{
"text": "imipenem",
"start": 59,
"end": 67
},
{
"text": "cilastatin",
"start": 68,
"end": 78
}
],
"adverse effect": [
{
"text": "neutropenic fever",
"start": 93,
"end": 110
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin. | {
"entities": {
"adverse effect": [
{
"text": "seizures",
"start": 13,
"end": 21
}
],
"drug": [
{
"text": "imipenem",
"start": 64,
"end": 72
},
{
"text": "cilastatin",
"start": 73,
"end": 83
}
]... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects. | {
"entities": {
"adverse effect": [
{
"text": "Proconvulsive",
"start": 0,
"end": 13
}
],
"drug": [
{
"text": "imipenem",
"start": 26,
"end": 34
},
{
"text": "cilastatin",
"start": 35,
"end": 45
}
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack. | {
"entities": {
"adverse effect": [
{
"text": "convulsions",
"start": 28,
"end": 39
},
{
"text": "seizure",
"start": 100,
"end": 107
},
{
"text": "seizure",
"start": 172,
"end": 179
}
],
"drug": [
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Gabapentin-induced mood changes with hypomanic features in adults. | {
"entities": {
"drug": [
{
"text": "Gabapentin",
"start": 0,
"end": 10
}
],
"adverse effect": [
{
"text": "mood changes",
"start": 19,
"end": 31
},
{
"text": "hypomanic",
"start": 37,
"end": 46
}
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We report two adults who received gabapentin (GBP) and subsequently developed behavioural side effects. | {
"entities": {
"drug": [
{
"text": "gabapentin",
"start": 34,
"end": 44
},
{
"text": "GBP",
"start": 46,
"end": 49
}
],
"adverse effect": [
{
"text": "behavioural side effects",
"start": 78,
"end": 102
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy. | {
"entities": {
"adverse effect": [
{
"text": "Acute pancreatitis",
"start": 0,
"end": 18
}
],
"drug": [
{
"text": "5-aminosalicylic acid",
"start": 78,
"end": 99
}
]
},
"relations": {
"adverse effect": [
{
"... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid. | {
"entities": {
"adverse effect": [
{
"text": "acute pancreatitis",
"start": 68,
"end": 86
}
],
"drug": [
{
"text": "5-aminosalicylic acid",
"start": 121,
"end": 142
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy. | {
"entities": {
"adverse effect": [
{
"text": "visual field constriction",
"start": 19,
"end": 44
}
],
"drug": [
{
"text": "vigabatrin",
"start": 75,
"end": 85
}
]
},
"relations": {
"adverse effect": [
{
"hea... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. | {
"entities": {
"drug": [
{
"text": "vigabatrin",
"start": 120,
"end": 130
}
],
"adverse effect": [
{
"text": "visual field constriction",
"start": 142,
"end": 167
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported. | {
"entities": {
"adverse effect": [
{
"text": "visual field constriction",
"start": 21,
"end": 46
}
],
"drug": [
{
"text": "vigabatrin",
"start": 77,
"end": 87
}
]
},
"relations": {
"adverse effect": [
{
"hea... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously. | {
"entities": {
"drug": [
{
"text": "vigabatrin",
"start": 107,
"end": 117
}
],
"adverse effect": [
{
"text": "visual field loss",
"start": 129,
"end": 146
}
]
},
"relations": {
"adverse effect": [
{
"head": ... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn. | {
"entities": {
"adverse effect": [
{
"text": "field defects",
"start": 4,
"end": 17
}
],
"drug": [
{
"text": "vigabatrin",
"start": 75,
"end": 85
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Depressive symptoms disappeared after interferon therapy was stopped. | {
"entities": {
"adverse effect": [
{
"text": "Depressive symptoms",
"start": 0,
"end": 19
}
],
"drug": [
{
"text": "interferon",
"start": 38,
"end": 48
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects. | {
"entities": {
"drug": [
{
"text": "interferon alpha",
"start": 38,
"end": 54
},
{
"text": "IFN-alpha",
"start": 56,
"end": 65
}
],
"adverse effect": [
{
"text": "psychiatric side effects",
"start": 163,
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent changes in serotonergic or noradrenergic neurotransmission caused by IFN-alpha. | {
"entities": {
"adverse effect": [
{
"text": "changes in serotonergic or noradrenergic neurotransmission",
"start": 102,
"end": 160
}
],
"drug": [
{
"text": "IFN-alpha",
"start": 171,
"end": 180
}
]
},
"relations": {
"adv... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity. | {
"entities": {
"drug": [
{
"text": "vancomycin",
"start": 73,
"end": 83
}
],
"adverse effect": [
{
"text": "vancomycin toxicity",
"start": 73,
"end": 92
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate. | {
"entities": {
"drug": [
{
"text": "vancomycin",
"start": 91,
"end": 101
}
],
"adverse effect": [
{
"text": "vancomycin toxicity",
"start": 91,
"end": 110
}
]
},
"relations": {
"adverse effect": [
{
"head": ... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen. | {
"entities": {
"adverse effect": [
{
"text": "morbidity",
"start": 68,
"end": 77
}
],
"drug": [
{
"text": "hyperbaric oxygen",
"start": 111,
"end": 128
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months. | {
"entities": {
"adverse effect": [
{
"text": "brown discolouration of the fingernails",
"start": 34,
"end": 73
}
],
"drug": [
{
"text": "4% hydroquinone in sorbolene cream",
"start": 103,
"end": 137
},
{
"text": "0.1% t... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Nail staining from hydroquinone cream. | {
"entities": {
"adverse effect": [
{
"text": "Nail staining",
"start": 0,
"end": 13
}
],
"drug": [
{
"text": "hydroquinone",
"start": 19,
"end": 31
}
]
},
"relations": {
"adverse effect": [
{
"head": {
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Gangrene of the fingertips after bleomycin and methotrexate. | {
"entities": {
"adverse effect": [
{
"text": "Gangrene",
"start": 0,
"end": 8
}
],
"drug": [
{
"text": "bleomycin",
"start": 33,
"end": 42
},
{
"text": "methotrexate",
"start": 47,
"end": 59
}
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
This supports the well-reported potential of bleomycin to trigger acral vascular toxicity. | {
"entities": {
"drug": [
{
"text": "bleomycin",
"start": 45,
"end": 54
}
],
"adverse effect": [
{
"text": "acral vascular toxicity",
"start": 66,
"end": 89
}
]
},
"relations": {
"adverse effect": [
{
"head":... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx. | {
"entities": {
"adverse effect": [
{
"text": "acute digital ischemia",
"start": 72,
"end": 94
},
{
"text": "gangrene",
"start": 99,
"end": 107
}
],
"drug": [
{
"text": "bleomycin",
"start": 152,
"end": 1... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Diarrhea-associated over-anticoagulation in a patient taking warfarin: therapeutic role of cholestyramine. | {
"entities": {
"adverse effect": [
{
"text": "Diarrhea-associated over-anticoagulation",
"start": 0,
"end": 40
}
],
"drug": [
{
"text": "warfarin",
"start": 61,
"end": 69
}
]
},
"relations": {
"adverse effect": [
{
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We present a case of significant over-anticoagulation temporally associated with a bout of protracted diarrhea in a patient on warfarin therapy. | {
"entities": {
"adverse effect": [
{
"text": "over-anticoagulation",
"start": 33,
"end": 53
},
{
"text": "diarrhea",
"start": 102,
"end": 110
}
],
"drug": [
{
"text": "warfarin",
"start": 127,
"end": 135... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
MI related to the use of activated and non-activated PCCs predominantly affects young patients who often have no preceding history of, or risk factors for, MI and tends to be associated with large cumulative doses of concentrate. | {
"entities": {
"adverse effect": [
{
"text": "MI",
"start": 0,
"end": 2
}
],
"drug": [
{
"text": "PCCs",
"start": 53,
"end": 57
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"text": "MI",
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors. | {
"entities": {
"drug": [
{
"text": "prothrombin complex concentrate",
"start": 69,
"end": 100
}
],
"adverse effect": [
{
"text": "myocardial infarction",
"start": 109,
"end": 130
}
]
},
"relations": {
"adverse effect": [
... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
We have safely used recombinant factor VIIa to treat bleeding in the immediate and long-term period following PCC-related MI. | {
"entities": {
"drug": [
{
"text": "PCC",
"start": 110,
"end": 113
}
],
"adverse effect": [
{
"text": "MI",
"start": 122,
"end": 124
}
]
},
"relations": {
"adverse effect": [
{
"head": {
"text": "M... | {
"entities": [
{
"label": "drug",
"description": "Names of drugs and chemical substances, including brand and generic names.",
"description_source": "mneb"
},
{
"label": "adverse effect",
"description": "Adverse effects: signs, symptoms, diseases, disorders or abnormal findi... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.